Using CT radiomics to better characterize ovarian cancer
Prospective Validation of CT Based Radiomic Models to Predict Surgical and Clinical Outcomes in Advanced Epithelial Ovarian Cancer
This project will try using advanced computer analysis of routine CT scans (radiomics) to predict treatment response and tumor features in adults with advanced epithelial ovarian cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 168 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Imperial College Healthcare NHS Trust Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT06817174 on ClinicalTrials.gov |
What this trial studies
This observational study collects pre-treatment portal-venous phase CT scans from adults with suspected or confirmed advanced epithelial ovarian cancer (FIGO stage ≥3B) who are planned for surgery and/or chemotherapy. Using radiomics, the team will extract quantitative imaging features from visible lesions (≥2 cm) and link those features to clinical data, histology, and treatment outcomes. No experimental interventions are given; researchers will analyze routine imaging and clinical records to build and test models that could predict prognosis or response. The work is led by Imperial College Healthcare NHS Trust with collaborators including the National Cancer Center, Korea.
Who should consider this trial
Good fit: Adults (≥18) with suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or higher), visible disease ≥2 cm on a portal-venous CT, able to give informed consent, and planned for active anticancer treatment are the intended participants.
Not a fit: Patients with no measurable disease on CT (<2 cm), those only fit for palliative care, pregnant individuals, or people with contraindications to contrast-enhanced CT are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, radiomic models could help doctors tailor surgery and chemotherapy plans by predicting which patients are more or less likely to respond.
How similar studies have performed: Previous radiomics studies in ovarian cancer and other tumors have shown promising correlations with prognosis and surgical outcomes but remain preliminary and are not yet part of standard clinical practice.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written (signed and dated) informed consent * Age 18 years or over * Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more) * Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery * Evaluable baseline portal venous phase CT scan prior to surgical or medical treatment for ovarian cancer * Disease visible on pre-treatment portal venous phase baseline CT scan (≥2cm) Exclusion Criteria: * Known contra-indication to CT with IV contrast (e.g. contrast allergy, renal failure, inability to lie flat); * Unable to give informed consent; * Known pregnancy; * No visible disease \<2cm on portal venous phase baseline CT scan; * Previous surgery for resection of an adnexal mass; * Significant artefact on CT image for example from metal prostheses that precluded meaningful segmentation of visible disease * Only fit for palliative care at initial presentation
Where this trial is running
London
- Imperial College NHS Healthcare Trust — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Christina Fotopoulou, MD, PhD
- Email: c.fotopoulou@imperial.ac.uk
- Phone: (+44) +44 (0)20 3313 3274
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.